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Purpose: The purpose of this study was to define the clinical features of aortic aneurysms 
occurring in heart transplant recipients. 
2Vdethods: Among the 734 patients who have undergone heart transplantation at out 
institution over the last 14 years, we have identified 12 patients (1.6% incidence) with 
aortic aneurysms (9 infrarenal, 3 thoracoabdominal), making this the largest reported 
series of aortic aneurysms (AA) in heart transplant recipients. 
Results: For nine of the 12 patients with AA (75%), the indication for transplantation was 
ischemic cardiomyopathy. This indication accounted for only 42% of the overall 
transplantation group; our data therefore show that the risk of infrarenal AA disease was 
higher for patients who underwent transplantation for ischemic ardiomyopathy than for 
other indications (p = 0.02). In two of the patients with thoracoabdominal AA, chronic 
dissection was identified as the specific AA cause, whereas all of the other patients in the 
study had nonspecific "atherosclerotic" AAs. All 12 patients were symptom free at the time 
ofinitial discovery of the AAs. Two of the patients with infrarenal AA were diagnosed with 
AAs before transplantation; for the seven remaining patients with infrarenal AAs, the 
mean time between transplantation a d AA discovery was 5.0 years (range 1.2 to 11.8 
years). Serial radiologic studies allowed us to determine the AA expansion rate in seven 
of the 12 patients. This rate varied from 0 to 2.53 cm/yr (mean 1.20 cm/yr; 1.0 cm/yr for 
infrarenal AA alone). Five patients with infrarenal AA underwent AA repair as the initial 
treatment. Three others underwent repair after their AAs significantly expanded rinder 
observation. Mean AA diameter at the time of repair was 6.9 cm. All three patients with 
thoracoabdominal AAs died of acute AA rupture before resection could be done, despite 
their initial asymptomatic state. AA diameters at time of rupture were 3.5, 6.0, and 11 cm. 
All of the eight patients with AA treated with surgery are alive and wer (median follow-up 
18 months). The only complication was acute heart transplant rejection, which occurred 
11 days after AA repair in one patient. 
Conclusions: Out data suggest that AA occurrence is more likely in patients who undergo 
heart ransplantation for ischemic heart disease than for other indications. Careful serial 
radiologic surveiUance is warranted in any heart transplant patient with an AA, because 
of the apparent potential for more rapid AA expansion in this patient population than in 
patients who do not undergo transplantation. We conclude that early repair of infrarenal 
AA is indicated because xceUent operative results and low morbidity rates can be achieved. 
An aggressive approach to thoracoabdominal AAs in this group may also be appropriate 
because of the apparent propensity to lethal rupture, sometimes at relatively smaU AA size. 
(J VASe SURG 1995;22:689-96.) 
The recent era of increasingly successful heart 
transplantation has wimessed a steady improvement 
in post-transplantation survival rates, with recently 
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reported survival rates of 90% at 1 year and 78% 
at 5 years. 1 Several reports have emphasized the 
susceptibility of this population of patients to extra- 
cardiac surgical disease, including peripheral vascular 
disease. 2-8 Of  particular note is the development of  
aortic aneurysms (AA) in these patients. Regardless 
ofwhether the aneurysm is rupmred at presentation, 
such cases can represent a significant challenge to the 
vascular surgeon. Additionally, the potential effect of 
posttransplantation mmunosuppression a d hemo- 
dynamic alterations on the growth rate of aortic 
aneurysms i of  great interest. 
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Despite the increasing size of the post-cardiac- 
transplant population, experience with aortic aneu- 
rysms in this group has been limited, with fewer than 
20 cases having been reported over the last 18 years 
in the form of case reports or series of 5 or fewer 
patients. 26'9a4 We report herein our experience with 
12 patients with clinically apparent AAs who have 
undergone heart transplantation, making this the 
largest reported series dealing with this topic. We 
review the incidence, clinical features, and expansion 
rate of AA in these patients. 
MATERIAL AND METHODS 
Patients with AA were identified by retrospective 
review of the records of all patients receiving 
orthotopic heart transplants at the University of 
Pittsburgh Medical Center (UPMC) between Janu- 
ary 1980 and August 1994. Further information 
about he identified patients was obtained by detailed 
review of their hospital and outpatient records, as 
weU as direct communication with patients and their 
families. AA size was determined in all cases by either 
computerized tomography or ultrasound examina- 
tion of patients. Standard statistical analysis, indu& 
ing chi square testing, was performed with a standard 
spreadsheet program (Microsoft Excel) on a personal 
computer. 
Posttransplantation monitoring of heart trans- 
plant recipients at UPMC is very thorough, with a 
loss-to-follow-np rate less than 2%. In cases of 
patient death, an attempt is made in every case to 
ascertain the cause of death, by autopsy whenevcr 
possible. 
RESULTS 
Between January 1980 and August 1994, 734 
patients underwent heart ransplantation at UPMC. 
No routine screening program for AA was in place, 
but 12 patients with AA were identified in this closely 
monitored group of patients. Of these, nine (1.2%) 
had infrarenal AA, and three (0.4%) had thoracoab- 
dominal AA (2 Crawford type II and 1 Crawford 
type IV). As shown in Table I, among patients 
undergoing transplantation for ischemic ardiomy- 
opathy, the chance of AA detection was 2.9%, a 
significantly higher rate than the 0.7% incidence 
among patients with other indications (p = 0.02). 
The difference was eren more significant when only 
infrarenal AA are considered (2.6% vs 0.2%, 
p < 0.01). 
Table II shows selected clinical characteristics of 
the 12 patients with AA. All patients were men. The 
mean age of the patients with infrarenal AA at time 
of transplantation was 54.8 years, whereas the mean 
age of the patients with TAA at heart ransplantation 
was 61.0 years. In all 12 patients, the AAs were 
discovered at an asymptomatic stare. Of the nine 
infrarenal AAs, only two were diagnosed before 
transplantation. Among the remaining seven patients 
with infrarcnal AA, the mean time between trans- 
plantation and AA discovery was 5.0 years (range 1.3 
to 11.7 years). All three TAAs were discovered after 
transplantation, at a mean interval of 2.0 years after 
transplant. The AA sizes at time of detection are 
shown in Table II (range 3.5 to 10 cm). 
Table III summarizes the clinical course of the 12 
patients after detection of the AAs. Of the nine 
patients with infrarenal AA, five tmderwent AA 
repair as the initial management ondetection of the 
AAs (mean AA size 6.7 cm). The other four patients 
were observed with serial imaging studies. Of these 
individuals, three (MS, SM, and WS), exhibited 
significant AA expansion during the observation 
periods (1, 2.3 and 6.4 years) and underwent AA 
repair. The fourth (JO) has had a stable AA size over 
a 1.2-year observation period. Interestingly, this is 
also the sole patient with an infrarenal AA who did 
not have ischemic heart disease as his indication for 
transplantation. Thus eight of the nine patients with 
infrarenal AA have undergone surgical repair (mean 
AA size at repair = 6.9 cm, range 4 to 10 cm). All of 
the surgically treated patients had standard AA repair 
with prosthetic grafts, with 24 to 48 hours of 
perioperative antibiotic treatrnent and stress steroid 
supplement. Gross examination of the AA revealed 
nonspecific "atherosclerotic" AA in all cases. Inter- 
rupti0n of the immunosuppressive regimen was 
minimized by nasogastric tube administration of 
medications, when necessary. The only complication 
was acute cardiac allograft rejection in one patient at 
11 days after surgery. The rejection episode was mild 
and occurred while the patient was receiving his 
standard immtmosuppressive regimen. He was suc- 
cessfully treated with antithymocyte globulin, but 
this therapy led to acute kidney failure requiring 
temporary dialysis. All eight patients are alive and 
weil at late follow-up (median follow-up 1.5 years 
after surgery). 
All three patients with TAA died of acute 
aneurysm rupture. In two cases (DF, MH), AA size 
measurements a sessed 1.5 and 6 months before 
rupture were believed to be acceptably low (6 and 3.5 
cm), and surgery was not recommended. In the third 
case (FL), the patient's TAA was initially measured at
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Table I. Frequency of detection of AA among transplant recipients grouped by indication 
for transplant 
Indication for transplant 
No. with AA No. with infrarenal AA 
Total no. with (% of patients with (% of patients 
specified indication specified indication) with specified indication) 
Ischemic ardiomyopathy 308 9 (2.9%) 8 (2.6%) 
Nonischemic cardiomyopathy 426 3 (0.7%) 1 (0.2%) 
Total 734 12 (1.6%) 9 (1.2%) 
p Value 0.02 0.004 
Table Il. Clinical features of patients in whom AA were detected 
Age at 
Indication for transplant Symptoms at AA detected Age at AA Initial AA size 
Patient Sex transplantation (yr) AA detection before transplant? detection (years) AA type (cm) 
CC M Ischemic 58 None No 63 Infrarenal 6.3 
FD M Ischemic 55 None No 59 Infrarenal 10 
JH M Ischemic 51 None No 62 Infrarenal 7 
CH M Ischemic 50 None No 57 Infrarenal 6 
SM M Ischemic 59 None No 60 Infrarenal 3.5 
JO M Idiopathic 58 None Yes 57 Infrarenal 4 
MS M Ischemic 56 None No 60 Infrarenal 4.4 
WS M Ischemic 53 None Yes 53 Infrarenal 4 
LT M Ischemic 54 None No 62 Infrarenal 4 
Mean (infra- 54.8 59.2 5.5 
renal group) 
DF M Idiopathic 59 None No 59 TAA (dis- 3.5 
secfion) 
MH M Idiopathic 66 None No 70 TAA 6 
FL M Ischemic 58 None No 60 TAA (dis- 4 
section) 
Mean (TAA 61.0 62.9 4.5 
group) 
4 cm, and observation was recommended. The 
patient was lost to follow-up for a 5-year interval, at 
the end of which he was admitted with back pain to 
the emergency department. A computed tomogra- 
phy study showed a very large AA (11 cm), hut the 
patient died of acute rupture in the emergency 
department before surgery could be performed. 
Autopsies howed that t-wo of the TAAs (patients FL, 
DF) were the result of chronic aortic dissection, 
whereas the third (patient MH) had a nonspecific 
"atherosclerotic" AA. 
Serial radiologic studies allowed us to determine 
the AA expansion rate in six patients with infrarenal 
AA, consisting of the four patients who were treated 
with serial observation, and t-wo additional patients 
who had previous imaging studies howing normal- 
sized aortas. Expansion rate data were also available 
in one patient with TAA (FL). Fig. 1 shows the 
average observed expansion rates of these seven AAs. 
The rate, which in all cases was measured in the 
posttransplantation period, varied from 0 to 2.53 
cm/yr (mean 1.2 cm/yr; 1.0 cm/year for infrarenal 
AA alone), over observation periods ranging from 
0.9 to 11.7 years (mean 4.0 years). When expansion 
was expressed as a percentage of the average AA size 
over the observation period, the mean expansion rate 
was found to be 21.5%/yr (20.4%/yr for infrarenal 
AA alone). 
Not surprisingly, the cardiac ejection fraction in 
the patients rose significantly after transplantation, 
from a mean pretransplantation value of 0.17 to a 
mean posttransplant value of 0.57 (p < 0.01). Of 
interest is that the only patient who did not undergo 
AA surgery or have rupture (JO) was also the only 
one who did not exhibit a significant increase in 
ejection fraction after transplantation (0.18 before 
transplantation to 0.25 after transplantation). Nine 
of the 12 patients exhibited new or worsened 
hypertension after transplantation, by use of the 
grading system recommended for reports dealing 
with lower extremity ischemia by the Ad Hoc 
Committee on Reporting Standards of the Society 
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Initial size(cm) 2.0 2.0 3.5 4.0 4.4 4.0 5.4 
Final size (cm) 7.0 6.0 6.0 4.0 6.8 8.7 11.0 
Rate (cm/year) 0.43 1.33 1.09 0.00 2.53 0.73 2.30 
Annual % Rate 9.5% 33.3% 23.0% 0.0% 45.2% 11.5% 28.1% 
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Fig. 1. Observed sizes and average xpansion rates of AAs in seven patients. Annual % rate 
refers to annual expansion rate measured as percentage of average AA size over observation 
period. All patients had infrarenal AAs except for FL, who had TAA. 
for Vascular Surgery/International Society for Car- 
diovascular Surgery, North American Chapter. is
DISCUSSION 
Since the initial report of Reitz et al. 3 in 1977, 
there have been several case reports and small series 
describing AAs in heart transplant recipients. 2,<5,9q2 
Such AAs have also been mentioned incidentally in 
other articles having a more general focus. 6a3,14 
Despite these numerous reports, the combined num- 
ber of previously reported cases is fewer than 20. In 
this study, we detail our experience with 12 patients 
with AAs, detected from among 734 cardiac allograft 
recipients over a 14-year period. We found a signifi- 
cantly higher AA incidence among patients who 
underwent transplantation for ischemic ardiomyop- 
athy, in comparison to patients with other indications 
(Table I, 2.9% vs 0.7%,p = 0.02). This finding is in 
agreement with previous reports, which have found 
most or all AAs in the ischemic cardiomyopathy 
group. 2"s The 2.9% incidence of AA in the ischemic 
cardiomyopathy group is similar to values reported 
by Reitz et al. 3 (2.7%) and Reichman et al. 2 (2%) but 
less than the 10.5 % incidence observed by Piotrowski 
et aL s AA detection in the last study was based on 
routine screening of transplant patients by ultra- 
sonography. Although our transplant patients are 
closely monitored and all of the AA in our series were 
detected at an asymptomatic stage, routine screening 
for AA was not used. This may account for the higher 
incidence reported by Piotrowski et aL s 
The clinical courses of the patients with infrarenal 
AA are instructive (Table III). Five patients under- 
weht AA repair soon after AA detection. Four of 
these had AA 6 cm or greater. Of the four patients 
who were observed with serial imaging studies, three 
exhibited significant AA expansion and came to 
surgery with large AAs. The one patient (JO) who 
had stable AA size was also the only patient with an 
infrarenal AA not of the ischemic cardiomyopathy 
subgroup. The mean AA expansion rate for the six 
patients with inffarenal AA in whom this parameter 
was available was 1.0 cm/year (Fig. 1). I fthe analysis 
is restricted to the ischemic cardiomyopathy sub- 
group (n = 5), the mean rate was 1.2 cm/yr. Our 
values are somewhat higher than the 0.7 cm/yr 
expansion rate observed by Piotrowsld et al.s The 
expansion rate of 0.7 cm/yr and the values reported 
in this smdy are greater than the ffequently cited rate 
of 0.2 to 0.4 cm/yr for AA in nontransplant 
patients. 16a7 Mthough the rate of AA expansion in 
nontransplant patients is not definitively estab- 
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Table III. Clinical course of patients after AA detection 
Last measured 
AA size in cm 
In#iM size Initial (interval 
Patient AA type (cm)  management after detection) 
Subsequent events 
(interval 




CC Infra 6.3 AA repair n/a 
FD Infra 10 AA repair n/a 
JH Infra 7 AA repair n/a 
CH Infra 6 AA repair n/a 
SM Infra 3.5 Observation 6 (2.3 yrs) 
JO Infra 4 Observation 4 (1.2 yrs) 
MS Infra 4.4 Observation 6.8 (1 yr) 
WS Infra 4 Observation 8.7 (6.4 yrs) 
LT Infra 4 AA repair n/a 
DF TAA 3.5 Observation 3.5 (1 yr) 
MH TAA 6 Observation no f/u size 









AA repair (1 yr) 
AA repair (6.4 yrs) 
n/a 
Died of rup- 
ture (1.5 yrs) 
Died of rup- 
ture (1.5 months) 
Died of rup- 

























InJ~a, Infrarenal; TAA, thoracoabdominal; n/a, not applicable; f/u, follow-up; yr, year. 
lished, 18 it is noteworthy that a recent review of 
several studies howed AA expansion rates varying 
from a low of 0.19 to a maximum of 0.74 cm/yr. 19 
Another usefu] way to describe xpansion rates is to 
express them as a percentage of the average AA size 
over the observation period. Calculated in this 
manner, the infrarenal AA expansion rate was found 
to be 20.4%/yr (Fig. 1), a larger value than the 
commonly quoted value of 10%/yr. Thus despite the 
uncertainty about the namral history of AA in the 
general population, the rates observed in this patient 
group do seem to be greater than those seen in 
nontransplant patients with AA. Our experience 
suggests hat infrarenal AAs found in heart ransplant 
patients exhibit a more aggressive course than the 
same lesions in nontransplant patients. 
All eight patients who underwent surgical AA 
repair have done weil (Table III). Routine surgical 
technique, perioperative antibiotics, and stress ste- 
roid supplementation were used in all cases. A single 
patient had development of cardiac allograft rejection 
11 days after AA repair but responded toappropriate 
therapy. No problems with infection or wound 
healing were observed, despite the immunosuppres- 
sive regimens used in these allograft recipients. 
Because of the aggressive clinical course of 
clinically apparent infrarenal AAs in these patients 
and because repair is weil tolerated, we believe that 
early surgical repair is indicated for all infrarenal AAs 
in heart ransplant recipients. If certain small AA are 
ler untreated, close follow-up is warranted. The role 
of routine screening for abdominal AA is not 
definitively established. Despite the fact that we did 
not use routine screening of our transplant patients 
during the period of this study, all of the AA in this 
study were diagnosed at an asymptomatic stage with 
the close clinical monitoring that we use for all 
transplant recipients. It is possible that some AA have 
gone unnoticed because of the lack of routine 
imaging. However, we are unaware of any adverse 
outcomes resulting from failure of AA diagnosis 
among our patients. Thus further study will be 
needed to determine the cost-effectiveness of routine 
screening for AA. 
The natural history of TAAs in heart ransplant 
recipients has not received attention in previous 
reports. Although our experience is limited to three 
cases, some tentative conclusions can be drawn. 
TAAs in this population clearly have the potential for 
a malignant course, becanse all three patients with 
TAA in our study died of AA rupture. In two cases, 
imaging studies done 1.5 and 6 months before death 
showed AA sizes of 3.5 and 6 cm. In the third patient 
(FL), rapid AA growth (2.3 cm/yr) was seen (Fig. 1), 
culminating in fatal rupture. Our practice and that of 
others has been to derer TAA repair in nontransplant 
patients until the size exceeds 6 cm. However, 
because of the apparent propensity in transplant 
patients for TAA rupture at small sizes, as weil as the 
potential for rapid growth, an aggressive approach to 
the repair of such aneurysms may be warranted. 
The reason for the apparently rapid expansion of 
AA in heart transplant recipients i  not dcfinitively 
known, but several factors have been postulated. He- 
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modynamic alterations after transplantation include 
increased ej ection fraction (0.17 to 0.57 in our smdy, 
p < 0.01 ) and new or worsened hypertension (seen 
in 75% of our patients). Hypertension may be the 
result of improved cardiac output or the effect of 
immunosuppressive agents such as cyclosporine or 
steroids. 2° Hemodynamic factors have been impli- 
cated by other authors as contributors to AA forma- 
tion or rupture. 21-2a In this context, it is notable that 
the one patient in our study (JO) who did not have 
AA repair or rupnlre was also the only patient who 
did not have a significant posttransplantation increase 
in ejection fraction (0.18 m 0.25). Other investiga- 
tors have implicated steroids as having a specific pro- 
aneurysmal effect. 24'25 
Our data show that clinically apparent AA for- 
mation occurs predominantly, but not exclusively, 
in the ischemic cardiomyopathy subgroup of heart 
transplant recipients. AAs in transplant patients 
seem to have a propensity for rapid expansion 
and exhibit a clinically aggressive course. Once 
detected, these lesions warrant immediate repair or 
at least very close observation. However, the cost- 
effectiveness of routine radiologic surveillance for 
AA in transplant patients is undetermined. We 
have found that infrarenal AA can be safely re- 
paired in this population, with low morbidity and 
mortality rates. An aggressive approach to repair 
of TAAs may be indicated in heart transplant 
patients, on the basis of our experience with such 
patients. 
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DISCUSSION 
Dr. Joseph A. Buda (New York, N.Y.). This report is 
the latest of several reports of patients who have undergone 
heart transplantation a d who have shown other manifes- 
tations of the complications of arteriosclerosis, ncluding 
expansion of aneurysms and other manifestations of 
peripheral vascular disease. 
The observations and conclusions conceming the 
management of AAs in these patients are important. 
Currently about 2000 heart transplantations are being 
performed annually, and the posttransplant survival rate, as 
reported by this group, are 90% at 1 year and about 78% 
at 5 years. Therefore we can expect the number of 
peripheral vascular procedures reqnired in this group to 
increase as the years go on. 
Heart transplantation has been done for ischemic 
cardiomyopathy in about half of the patients. A high 
incidence of anenrysms has been observed in this group. 
Coupled with'this is the observed increased rate of 
progression of atherosclerotic changes associated with the 
immunosuppressive agents used, namely, cyclosporine and 
steroids. The possible role of hypertension as a result of 
improved ejection fraction and immunosuppression has 
been discussed concerning the acceleration of the athero- 
sclerosis. The increased survival rate of heart transplanta- 
tion with the addition of cydosporine has made heart 
transplantation almost a routine operation, a form of 
treatment for end-stage cardiac disease. 
The specific message delivered by this smdy and by 
other reports is that heart ransplant patients can under go 
operation with no significant increased risk of complica- 
tions, namely, difficulties with healing, infection, bleeding, 
or rejection. In addition, patients who have had cardiac 
allografts are not necessarily ata higher operative risk when 
undergoing operations for peripheral vascular disease. The 
operative risk of coronary artery disease in patients who 
have other manifestations or complications of peripheral 
vascular disease may weil be decreased by the presence of a 
better functioning, transplanted heart. 
I agree with the authors that routine ultrasonography 
or computed tomography surveillance for aneurysms can 
be significant in monitoring patients who have had a 
cardiac graft, especially when the indication for the 
transplantation is ischemic cardiomyopathy. Accelerated 
atherosclerotic changes in the coronary vessels of trans- 
planted hearts has been a major cause for late transplanta- 
tion failure. Did any ofyour patients treated for aneurysm 
have this problem as weil? 
It is important to appreciate that this group of patients 
with aneurysmal disease can undergo successful operation 
and without any undue risk of complications. It is also 
important to note the progression of atherosderosis 
potentially accelerated, and this should be followed very 
closely. 
Dr. Satish C. Muluk. The issue of accelerated 
atherosclerosis in these heart transplant recipients is im- 
portant. When looking at the figures from the transplant 
unit at Pittsburgh, there's roughly a 40% incidence of 
accelerated atherosclerosis occurring at 5 years in these 
patients in the coronary circulation. However, none of the 
12 patients in this series exhibited that problem. I don't 
know if that's a meaningful statement or not, because this 
was a relatively small fraction of the total transplant 
population. 
Another important issue is whether atherosclerosis is 
accelerated in the nonaortic peripheral circulation; it's 
certainly known to be accelerated in the coronary circula- 
tion. Although we haven't carefully examined those num- 
bers yet, we don't perceive that there's amarked increase in 
the occurrence of atherosclerosis in the peripheral circula- 
tion in these patients. 
Dr. Jesse A. Blurnenthal (New York, N.Y.). Was 
there any histologic study, specific chemistry done on these 
aneurysm walls to determine whether they are any differ- 
ent? Dr. Tilson's group performed a smdy dealing with the 
incidence in blotchy mice of spontaneous occurrence of 
aneurysms. All aneurysms ruptured when these mice were 
pretreated with steroids. Is there anything different in the 
histologic ondition? 
Dr. Muluk. We have t-wo types of pathologic infor- 
mation. One is the autopsy data on the patients with TAA 
who died. The two of them seemed to have fairly typical 
dissection at autopsy, and another had a typical, so-called 
atherosclerotic or degenerative thoracic aneurysm. The 
infrarenal aneurysm data are not as thorough in the sense 
that what we have are the operative reports of the surgeons 
who operated on those patients, and those aneurysms 
appeared to be typical degenerative atherosclerotic infra- 
renal aneurysms. 
Dr. Henry D. Berkowitz (Philadelphia, Pa.). I want 
to report one case of an expanding TAA repaired success- 
fully. I too was surprised that the patient was hemody- 
namically stable in spite of aortic clamping. These patients' 
conditions are more or less like the conditions of other 
patients, with one exception: cyclosporine-induced ki ney 
failure may be present, which increases the risk of 
suprarenal c amping. Our patient had a creatinine level of 
3 to 4 to start with and ukimately underwent long-term 
dialysis. 
Dr. Muluk. Certainly those are all important points. 
Despite the denervation of their hearts, the patients eem 
to have no trouble tolerating cross-clamping or the 
postoperative h aling requirements. 
Dr. John V. White (Philadelphia, Pa.). We frequently 
and vigorously debate the role of the inflammatory ceU 
infiltrate in the aortic wall of abdominal aortic aneurysms. 
You gave us two hypotheses to explain why these patients 
may have an accelerated rate ofaneurysm growth after heart 
transplantation. I would like to suggest a third hypothesis 
for you to comment on: the role of the inflammatory cell 
infiltrate is to respond to injury rather than to induce it. 
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Perhaps by inhibiting the inflammatory cell response you 
may be preventing a mechanism of repair. 
If you postulate that the steroids have an effect on the 
biomechanical integrity of the aortic wall and thus permit 
a more accelerated rate of growth, are there any additional 
technical precautions that must be taken? For instance, do 
you reinforce your anastomosis by sandwiching it between 
layers of Dacron to maintain suture integrity? 
Dr. Muluk. In response to your first question, it's a 
very interesting hypothesis; I only wish that we had more 
pathologic information, for example, acmal aortic wall 
specimens from these patients who had undergone trans- 
plantation and had development of aneurysms, that might 
shed some light. But it's certainly aviable hypothesis that 
the inflammatory cell response is important in preserving 
aortic integrity. Unfortunately, we don't have any data to 
support or refute that. 
With regard to the other issue of specific technical 
considerations, all of these patients had fairly straight, 
standard repairs. There were no special precautions taken, 
and the aorta proximal to the aneurysm appeared to be of 
good quality and seemed to hold the sutures qnite weil. 
Dr. Jon R. Cohen (New Hyde Park, N.Y.). I am 
concerned about not knowing the age of the patients in the 
ischemic ardiomyopathy group verses the other patients. 
I don't know ifyou have the data, but I have an impression 
that if the patients with cardiomyopathy are older, the 
incidence of aneurysms in your group is probably the same 
as it would be in the namral population. 
There is a significant amount of data to suggest hat 
aneurysms may occur as a result of an inflammatory 
response to the aortic wall. In the presence of immuno- 
suppression, one would then suspect that aneurysms would 
occur less frequently or grow more slowly. 
Dr. Muluk. In terms of the incidence of aneurysms in
this group, we report that in the ischemic group the 
incidence was 2.7%. Actually, I suspect hat's not a great 
deal higher than the incidence in the general population, 
although I taust say we didn't look at numbers in the 
general population in an age-matched group very carefully. 
On the other hand, I think our message isthat when an 
aneurysm does develop in these patients for whatever 
reason, they behave in a more aggressive fashion, more of 
them end up coming to operation, and what expansion rate 
data we have shows that they can exhibit very high rates of 
expansion. 
Dr. Luis A. Queral (Baltimore, Md.). Your institution 
is renowned for its extraordinary experience in many 
different types of transplantation patients. Have you 
studied groups of patients after kidney transplantation, 
which is more common, to &termine whether you can 
answer a number of the questions that have been posed? 
Dr. Muluk. Although we do intend to look at those 
issues, we have not yet. We don't perceive that there is a 
significant incidence of AA formation in patients under- 
going kidney transplantation, but obviously they repre- 
sented a wholly different group of patients. Unlike the 
patients with ischemic cardiomyopathy who represent a
subgroup of patients that we typically see with develop- 
ment of AAs, the kidney transplant group is a different 
group of patients, and perhaps that accounts for the 
difference. 
